Israeli drugmaker Teva is the target of an EU antitrust investigation over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, the European Commission said ...
WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback